<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286325</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00013763</org_study_id>
    <nct_id>NCT00286325</nct_id>
  </id_info>
  <brief_title>Rituximab in the Treatment of Patients With Bullous Pemphigoid</brief_title>
  <official_title>Rituximab in the Treatment of Patients With Bullous Pemphigoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety of treatment of bullous pemphigoid in patients resistant
      to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bullous pemphigoid (BP) is an autoimmune blistering disease characterized clinically by the
      presence of severely itchy, tense blisters located over the trunk and extremities. BP is the
      most common of the autoimmune blistering diseases with an incidence of approximately 10 per
      1,000,000 population(1;2). In addition, BP occurs more frequently in the elderly. Routine
      histopathology reveals a sub-epidermal blister most often with large numbers of eosinophils.
      Direct immunofluorescence of the skin of patients with BP reveals a linear band of C3 and IgG
      at the basement membrane zone. Examination of the sera of patients shows the presence of a
      circulating anti-basement membrane zone autoantibody. This antibody has been found to be
      directed against a 180 kd protein of the basement membrane zone type XVII collagen (BPAg2)
      and against a 230 kd protein (BPAg1) found in the epidermal hemi-desmosome(3;4).

      BP is a severe disease most often requiring therapy with high dose systemic corticosteroids
      (0.75 - 1.0 mg/kg/day) often for months(5). In addition, relapses are common and the
      additional use of immunosuppressive drugs such as azathioprine, methotrexate, cyclosporine A
      and others are needed to minimize the dose of systemic corticosteroids. The 1-year mortality
      of BP has been estimated to range from 10 - 30%(1;6). Currently treatment of patients with BP
      consists of initial use of systemic corticosteroids (0.75 - 1.0 mg/kg/day). Control of
      symptoms and new blister formation is most often achieved within 1 month and systemic
      corticosteroids are then tapered. As many as 33 - 50% of patients may not be able to be
      tapered to clinically acceptable levels of systemic corticosteroids, requiring the addition
      of systemic immunosuppression often with azathioprine. Approximately 66% of patients require
      long term treatment with immunosuppressive medication to maintain control of their
      blistering.(5;7;8) The need for long term systemic corticosteroid therapy often with systemic
      immunosuppression in an elderly population results in a significant morbidity and mortality
      in patients with BP. New therapeutic interventions that would potentially allow for the more
      rapid discontinuation of prednisone, avoidance of systemic immuno- suppression and perhaps
      earlier clinical relapse would be of substantial benefit to patients with BP. The clinical
      and laboratory data has demonstrated that BP is an autoantibody mediated blistering disease.
      Taken together these observations suggest that the use of anti-CD20 antibody (Rituxan) may be
      useful in the treatment of patients with BP. We have previously treated a patient with BP and
      graft versus host disease with anti-CD20 and anti-CD25 and were able to achieve clinical and
      serological remission within 4 weeks of initiation of therapy(9). In addition, others and we
      have successfully utilized Rituxan for the treatment of pemphigus vulgaris, another
      autoantibody mediated, autoimmune blistering disease(10-15)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Cessation of New Blister</measure>
    <time_frame>1 year</time_frame>
    <description>The first study visit in which patient reported and was confirmed to have no new blister or lesion formation .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Corticosteroid Dose of 25% of Starting Dose or 10 mg/Day by Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG Anti Bullous Pemphigoid (BP) 180 Measured in Units by ELISA at Week 24.</measure>
    <time_frame>Week 0 and at 24 weeks</time_frame>
    <description>IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B Cell Number at Week 24</measure>
    <time_frame>Week 0 and at 24 weeks</time_frame>
    <description>Peripheral blood B cell number at week 24 compared to B cell number at week 0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <arm_group>
    <arm_group_label>Treatment Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label study all subjects treated with rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Infusion of 1000 mg of rituximab on day 0 and day 14</description>
    <arm_group_label>Treatment Rituximab</arm_group_label>
    <other_name>rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with autoimmune blistering skin diseases with clinical, histologic and
             immunological criteria confirming the diagnosis of bullous pemphigoid

          -  Ongoing disease activity on 17.5 mg/day of prednisone or more

        Exclusion Criteria:

          -  Current use of other immunosuppressive therapy such as azathioprine, cytoxan or
             mycophenolate mofetil within the last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Hall, III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003 Feb;48(2):455-9.</citation>
    <PMID>12571855</PMID>
  </reference>
  <reference>
    <citation>Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, Rai KR. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002 Oct;16(10):2092-5.</citation>
    <PMID>12357362</PMID>
  </reference>
  <reference>
    <citation>Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002 Oct;61(10):883-8.</citation>
    <PMID>12228157</PMID>
  </reference>
  <reference>
    <citation>Maloney DG, Grillo-LÃ³pez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997 Oct;15(10):3266-74.</citation>
    <PMID>9336364</PMID>
  </reference>
  <reference>
    <citation>McLaughlin P, Grillo-LÃ³pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.</citation>
    <PMID>9704735</PMID>
  </reference>
  <reference>
    <citation>Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9.</citation>
    <PMID>12640069</PMID>
  </reference>
  <reference>
    <citation>Piro LD, White CA, Grillo-LÃ³pez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999 Jun;10(6):655-61.</citation>
    <PMID>10442187</PMID>
  </reference>
  <reference>
    <citation>Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435-45.</citation>
    <PMID>7506951</PMID>
  </reference>
  <reference>
    <citation>Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001 Aug 15;98(4):952-7.</citation>
    <PMID>11493438</PMID>
  </reference>
  <reference>
    <citation>Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002 May 15;99(10):3872-3.</citation>
    <PMID>12014370</PMID>
  </reference>
  <reference>
    <citation>Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002 Feb;87(2):189-95. Erratum in: Haematologica 2002 Mar;87(3):336.</citation>
    <PMID>11836170</PMID>
  </reference>
  <reference>
    <citation>Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol. 1997 May;136(5):694-8.</citation>
    <PMID>9205501</PMID>
  </reference>
  <reference>
    <citation>Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol. 2003 Jul;28(4):366-8.</citation>
    <PMID>12823293</PMID>
  </reference>
  <reference>
    <citation>Diaz LA, Ratrie H 3rd, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, Giudice GJ. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest. 1990 Oct;86(4):1088-94.</citation>
    <PMID>1698819</PMID>
  </reference>
  <reference>
    <citation>Dupuy A, Viguier M, BÃ©dane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004 Jan;140(1):91-6.</citation>
    <PMID>14732665</PMID>
  </reference>
  <reference>
    <citation>Giudice GJ, Liu Z, Diaz LA. An animal model of bullous pemphigoid: what can it teach us? Proc Assoc Am Physicians. 1995 Jul;107(2):237-41. Review.</citation>
    <PMID>8624858</PMID>
  </reference>
  <reference>
    <citation>Goebeler M, Herzog S, BrÃ¶cker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003 Oct;149(4):899-901.</citation>
    <PMID>14616397</PMID>
  </reference>
  <reference>
    <citation>Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003 Mar;148(3):602-3.</citation>
    <PMID>12653767</PMID>
  </reference>
  <reference>
    <citation>Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. Arch Dermatol. 2002 Mar;138(3):385-9. Review.</citation>
    <PMID>11902990</PMID>
  </reference>
  <reference>
    <citation>Korman NJ. Bullous pemphigoid. The latest in diagnosis, prognosis, and therapy. Arch Dermatol. 1998 Sep;134(9):1137-41. Review.</citation>
    <PMID>9762028</PMID>
  </reference>
  <reference>
    <citation>Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993 Nov;92(5):2480-8.</citation>
    <PMID>7693763</PMID>
  </reference>
  <reference>
    <citation>Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999 Aug 21;354(9179):667-72. Review.</citation>
    <PMID>10466686</PMID>
  </reference>
  <reference>
    <citation>Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998 Apr;134(4):465-9.</citation>
    <PMID>9554299</PMID>
  </reference>
  <reference>
    <citation>Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, Prudlo C, Pawelczyk B, Messmer EM, Schuhmann M, Sinkgraven R, BÃ¼chner L, BÃ¼dinger L, Pfeiffer C, Sticherling M, Hertl M, Kaiser HW, Meurer M, Zillikens D, Messer G. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002 Jul;138(7):903-8.</citation>
    <PMID>12071817</PMID>
  </reference>
  <reference>
    <citation>Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002 Nov;47(5):785-8.</citation>
    <PMID>12399777</PMID>
  </reference>
  <reference>
    <citation>Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell. 1981 Jun;24(3):897-903.</citation>
    <PMID>7018697</PMID>
  </reference>
  <reference>
    <citation>Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002 Sep;30(5):327-9.</citation>
    <PMID>12209356</PMID>
  </reference>
  <reference>
    <citation>Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992 Apr;26(4):585-9.</citation>
    <PMID>1597545</PMID>
  </reference>
  <reference>
    <citation>Gault MH, Purchase L. Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? CMAJ. 1992 Sep 15;147(6):845-7.</citation>
    <PMID>1285757</PMID>
  </reference>
  <reference>
    <citation>Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP; British Association of Dermatologists. Guidelines for the management of bullous pemphigoid. Br J Dermatol. 2002 Aug;147(2):214-21.</citation>
    <PMID>12174090</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2006</study_first_submitted>
  <study_first_submitted_qc>February 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <results_first_submitted>April 4, 2011</results_first_submitted>
  <results_first_submitted_qc>September 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2012</results_first_posted>
  <last_update_submitted>April 9, 2013</last_update_submitted>
  <last_update_submitted_qc>April 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with bullous pemphigoid were recruited in dermatology clinics from 2005 - 2009.</recruitment_details>
      <pre_assignment_details>Patient were screened for appropriate diagnosis, disease activity, prednisone dosage before entry into the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treated</title>
          <description>Open label study subjects all treated with rituximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated</title>
          <description>Open label study subjects all treated with rituximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to Cessation of New Blister</title>
        <description>The first study visit in which patient reported and was confirmed to have no new blister or lesion formation .</description>
        <time_frame>1 year</time_frame>
        <population>Excluded subject with diagnosis of epidermolysis bullosa acquisita , made after study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Open label study subjects all treated with rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to Cessation of New Blister</title>
          <description>The first study visit in which patient reported and was confirmed to have no new blister or lesion formation .</description>
          <population>Excluded subject with diagnosis of epidermolysis bullosa acquisita , made after study entry.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="13" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint</title>
        <description>The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE.</description>
        <time_frame>1 year</time_frame>
        <population>The safety analysis was performed on all subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Open label study subjects all treated with rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint</title>
          <description>The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE.</description>
          <population>The safety analysis was performed on all subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment emergent adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Corticosteroid Dose of 25% of Starting Dose or 10 mg/Day by Week 24</title>
        <description>Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less</description>
        <time_frame>24 weeks</time_frame>
        <population>Excluded subject with epidermolysis bullosa acquisita diagnosed after study entry.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Open label study subjects all treated with rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Corticosteroid Dose of 25% of Starting Dose or 10 mg/Day by Week 24</title>
          <description>Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less</description>
          <population>Excluded subject with epidermolysis bullosa acquisita diagnosed after study entry.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgG Anti Bullous Pemphigoid (BP) 180 Measured in Units by ELISA at Week 24.</title>
        <description>IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24,</description>
        <time_frame>Week 0 and at 24 weeks</time_frame>
        <population>Excluded subject with diagnosis of epidermolysis bullosa acquisita made after study entry, excluded one subject with no circulating antibodies measured at either time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Open label study subjects all treated with rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>IgG Anti Bullous Pemphigoid (BP) 180 Measured in Units by ELISA at Week 24.</title>
          <description>IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24,</description>
          <population>Excluded subject with diagnosis of epidermolysis bullosa acquisita made after study entry, excluded one subject with no circulating antibodies measured at either time point.</population>
          <units>Elisa Units</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="6" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon comparing week zero antibody value in units to week 24 antibody value in units</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0156</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>B Cell Number at Week 24</title>
        <description>Peripheral blood B cell number at week 24 compared to B cell number at week 0</description>
        <time_frame>Week 0 and at 24 weeks</time_frame>
        <population>excluded subject with epidermolysis bullosa acquisita diagnosed after study entry</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Open label study subjects all treated with rituximab</description>
          </group>
        </group_list>
        <measure>
          <title>B Cell Number at Week 24</title>
          <description>Peripheral blood B cell number at week 24 compared to B cell number at week 0</description>
          <population>excluded subject with epidermolysis bullosa acquisita diagnosed after study entry</population>
          <units>B cells per microliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" lower_limit="1.41" upper_limit="137.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison of B cell number at week 0 to b cell number in participants at week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0078</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse events related or possibly related to study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Treated</title>
          <description>Open label study subjects all treated with rituximab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label trial of rituximab in the treatment of 7 patients with the autoimmune blistering disease bullous pemphigoid.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Russell P Hall</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-3110</phone>
      <email>hall0009@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

